// App-Quantinova.ai

370 : The PI3K inhibitor, taselisib (GDC-0032), has enhanced potency in PIK3CA mutant models through a unique mechanism of action

Researchers

Presenter

  • Kyle A. Edgar

Principal Investigators

  • Kyung Song

  • Stephen Schmidt

  • Don Kirkpatrick

  • Lilian Phu

  • Michelle Nannini

  • Rebecca Hong

  • Eric Cheng

  • Amy Young

  • Deepak Sampath

  • Lori S. Friedman

Medical Centers

  • Roche/Genentech, South San Francisco, CA

Locations

  • United States

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Solid malignancies

Biomarkers

  • Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit alpha isoform

Drug/Treatment

  • Taselisib

Outcome

  • N/A

Study Design

  • N/A

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved